Introduction lationship with the cysteine protease inhibitor cystatin.
Latexin, or tissue carboxypeptidase inhibitor (TCI), is
Results the only known mammalian carboxypeptidase inhibitor (CPI), and recombinant rat latexin has been shown to Latexin Is Macrophage Enriched and Inducible inhibit pancreatic carboxypeptidase A1 (CPA1), CPA2
In light of a possible role for latexin in inflammation, we (K i w3 nM), and CPA3 (mast cell carboxypeptidase, K i examined expression in macrophages, the major cell 16 nM) (Normant et al., 1995) . Comprising over 220 resitype recruited to acute and chronic inflammatory sites. dues, the protein is significantly larger than CPIs from
We have previously reported extensive analyses of plants and parasites (40-70 residues). Furthermore, lagene expression profiles in mouse macrophages from texin lacks the conserved 7-residue C terminus of these several mouse strains (Wells et al., 2003a) . These analyshorter CPIs that interacts with CPA in a substrate-like ses indicate that the gene encoding latexin forms part manner (Reverter et al., 2000) . The loss of the C termiof a set that is highly enriched in macrophages comnus suggests that latexin and the plant/parasite CPIs pared to other cell types and tissues, and is highly exhave distinctly different mechanisms of CPA inhibition. pressed in macrophage-rich tissues such as spleen and Latexin was first identified as a marker of neurons in liver (Wells et al., 2003b) . The latexin gene also fell within a cluster of genes induced in macrophages by the major lineage-specific growth factor, colony stimu-*Correspondence: j.martin@imb.uq.edu.au lating factor 1 (CSF-1), in combination with the pathoases or protease inhibitors. By comparison, TIG1 gene expression is also high in macrophages but does not gen product, lipopolysaccharide (LPS).
To confirm the latexin expression profile identified by change upon stimulation. using cDNA microarrays, we performed real-time PCR analysis in LPS-stimulated bone marrow-derived macroStructure of Latexin Based upon its expression profile in macrophages, laphages in the presence or absence of CSF-1. Latexin mRNA was, indeed, expressed at high levels in macrotexin and its target CPA represent potential targets for therapeutic intervention in chronic inflammatory disease. phages, and it was further induced by a combination of LPS and CSF-1 (Figure 2 ). Other genes induced by LPS As no latexin homologs with known structures could be identified, we determined its structure by X-ray crystalin murine macrophages included CPA3 (mast cell CP), a known interaction partner of latexin, carboxypeptilography by using MAD methods and SeMet-labeled protein. The structure has one molecule in the asymdase D (this has been noted previously, Hadkar and Skidgel, 2001), and the cysteine protease inhibitors metric unit and was refined at 1.83 Å resolution (Table 1) . Although there is no evidence of internal symmetry cystatin C and cystatin F (Figure 2) . Indeed, w8% of genes upregulated under this stimulation encode protefrom the polypeptide sequence, the crystal structure re-neously giving an rmsd of 2.1 Å for the C α atoms of 142 aligned residues (Figure 3) . The major structural differences between the two domains are variations in β strand lengths and different loop conformations and sizes. This is particularly striking for the loop connecting the first β strand and the α helix of each domain (β1-α1 and β6-α3, respectively). In domain 2, this loop comprises 11 residues (residues 121-131) that protrude from the core, while the equivalent loop in domain 1 is formed from five residues (residues 4-8) ( Figure 1B) . Furthermore, main comprises a five-stranded antiparallel β sheet wrapped around an α helix. The sequence identity bein the genes encoding both human and mouse latexin, the position between domains 1 and 2 corresponds to tween the two domains is w11% after structural alignment ( Figure 1B ), yet the C α atoms of 84 residues of an intron-exon boundary, with each domain encoded by three exons (data not shown). These data suggest domains 1 and 2 overlay with an rmsd of 1.9 Å. Extraordinarily, the pseudosymmetry is such that both dothat latexin may have evolved from an ancestral cystatin-like protein as a consequence of a gene duplicamains can be superimposed on the other, simulta- quence to the proCPB region described above, and it also includes a loop equivalent to one of the papainproteins that are related overall by only 30% identity suggests that the cis form of the peptide bond will also interacting regions of the cystatin human Stefin B (170-RNDDFI-175 of latexin, corresponding to VAGT of be present in TIG1 and the Xenopus and ovocalyxin proteins. Furthermore, the position of the cis-proline human Stefin B, highlighted in Figure 1B ). Some conserved residues also map to this area of the surface motif on a protruding loop is suggestive of a protein interaction surface. (Figure 3D ), though this analysis is hampered by the low number of latexin sequences available. compared to human latexin (due to substitutions of Lys159 to Tyr, Ile62 to Tyr, Glu33 to Val, and Gln18 to Conservation of a cis-Proline Motif Leu), and the negative patch at the helix 2 end of the The structure of latexin incorporates a cis-peptide cleft is reduced in size. Furthermore, the residues definbond between residues Ile122 and Pro123. These resiing the heparin binding site identified in the mouse ladues are located in a protruding loop between the first texin structure, and also present in the human and rat β strand (β6) and α helix (α3) of domain 2. The density latexin isoforms, are not conserved in TIG1. in this region is well defined (Figure 3) , and the sequence in this region (IPDXXG) is conserved throughout the latexin/TIG1 family of proteins (Figure 1) . Indeed, Discussion with four of six residues conserved in all eight proteins, this is the most highly conserved motif in the entire seLatexin is the only known mammalian carboxypeptidase inhibitor. We have found that latexin is expressed quence. This high degree of conservation in a family of mediate secretion. In this respect, latexin could resemble the serpin plasminogen activator inhibitor type 2 (PAI-2), which is a cytoplasmic protein located and regulated quite differently from its target, plasminogen activator (Costelloe et al., 1999) . However, in mast cells, latexin has a granular localization and associates with a subpopulation of vesicles (Uratani et al., 2000) , and we have confirmed that latexin is also expressed in a discrete granule population in macrophages (A. Burrows, D.A.H., and S.K., unpublished data).
Latexin Comprises Two Cystatin-like Folds

Structure of TIG1
Latexin is thought to be a noncompetitive inhibitor of CPA (Normant et al., 1995) . This mode of inhibition makes it difficult to predict putative interaction sites, because the binding site may not necessarily involve the enzyme active site. Analysis of the latexin structure reveals a number of features that could represent protein interaction sites, without the need to invoke conformational changes. The electrostatic surface of latexin reveals a basic patch formed by residues from the α helices of both subdomains (Lys18 and Lys159). The two subdomains are arranged so that there is a cleft in this part of the structure that could accommodate a peptide chain. Another intriguing feature is the protruding nature of the loop incorporating a cis-peptide and comprising residues 121-131. Clearly, it is there for a entirely unexpected was the striking similarity between Nevertheless, the available data strongly suggest a the subdomains of latexin and proteins of the cystatin/ role for CPA and latexin in inflammation, and other CPs, monellin superfamily (Figure 4 ). This similarity suggests including CPM, have been shown to correlate with the possiblity that latexin may have cysteine protease macrophage cytotoxic activity (Rehli et al., 2000) . CPA inhibitor activity. However, the residues in cystatins that has been reported to be involved in the production or are involved in binding are conserved within the cysregulation of several proinflammatory mediators. In vitatin family, but are not present in latexin. Indeed, the tro, CPA from mast cells degrades endothelin-1, raising sequence similarity between latexin and the cystatins the possibility that it limits endothelin-mediated vasois very low. constriction and proliferation (Metsarinne et al., 2002) .
The sequence similarity between latexin and TIG1 Pancreatic CPA has also been shown to convert the suggests that the latter may have protease inhibitor acpotent leukotriene C4 to the less potent leukotriene F4 tivity, though this is not yet tested to our knowledge. by hydrolysis of an amide bond, again suggesting a Similarly, there is no evidence that latexin plays a tumor negative role in inflammation (Reddanna et al., 2003) . suppressor role, though its partner protein CPA3 has However, purified bovine CPA can induce NFκB-depenbeen shown to be induced in prostate cancer cells (Hudent TNFα production from macrophages, suggesting a ang et al., 1999). However, if sequence identity between proinflammatory role (Jaffray et al., 2000) . The balance latexin and the C-terminal domain of TIG1 translates to between CPA and latexin could thus lead to either enstructural and functional similarity, it is possible that hancement or inhibition of inflammation, depending on TIG1 tumor suppressor function could be a conseother mediators present.
quence of extracellular proteolysis inhibition. This has One puzzling aspect is that latexin contains no signal parallels elsewhere in tumor biology; for example, the serine protease inhibitor maspin is a tumor suppressor peptide or predicted hydrophobic segments that could Alignments between the proteins were generated by CLUSTALX quantitative real-time PCR performed by using the LightCycler-(Jeanmougin et al., 1998) with default parameters. Models for the DNA Master SYBR Green I kit (Roche). The PCR was performed by C-terminal region of rat, mouse, and human TIG1 corresponding to using an ABI Prism machine (Applied Biosystems): 1 min hot start the latexin sequence were constructed by using MODELLER (Sali at 94°C, followed by 45 cycles of 1 s at 94°C, 10 s at 60°C, and 15 and Blundell, 1993) with mouse latexin structure as the template. s at 72°C. cDNA levels during the linear phase of amplification were
The highest refinement level in HOMOLOGY (INSIGHTII, Accelrys) normalized against hypoxanthine phosphoribosyltransferase conwas used. The modeling procedure was iterative; in each iteration, trols. Assays were done in triplicate, and mean ± SD was deter-10 models were constructed and compared. The lowest energy mined. Primers used for the amplification of murine latexin: forward structure was used for further refinement. The stereochemical qual-5#-TTCGAAGGAGAAATCGGCAA-3# and reverse 5#-GGGATGTCC ity of models was checked by using PROCHECK (Laskowski et al., TGTGCTTCCAG-3#. 1993), as implemented in the Biotech validation suite at 1.9 Å resolution.
Expression and Purification
Sulfate binding pockets were identified by using GRID (Good-A pool of cDNA species generated by using mRNA extracted from ford, 1985) with a charged oxygen of a sulfate or phosphate used murine bone marrow-derived macrophages treated with LPS over as a probe with grid spacing of 0. eters were set to defaults. The cycling conditions included initial denaturation for 2 min at 95°C, followed by 30 cycles of denaturation at 95°C for 30 s, annealing at 55°C for 45 s, and elongation at 68°C for 1 min. Acknowledgments The PCR product was cloned into pENTR/D-TOPO vector with GATEWAY (Invitrogen). The latexin gene was transferred into pDEST-17 expression vector and expressed in E. coli as an N-terWe thank staff at BL8.2.2 for help in data collection, Catherine Latham for help with data collection and processing, and Alun Jones minal His-tag fusion protein.
The protein was expressed in E. coli by autoinduction (W. Studier, for mass spectrometry. Crystallographic data were measured at the Advanced Light Source, which is supported by the Director, Office personal communication). A colony from an LB-Amp plate was inoculated into 1-2 ml defined minimal medium containing glucose of Science, Office of Basic Energy Sciences, Materials Sciences
